Health Canada
Ocugen to Expand Phase III Gene Therapy Study in Retinitis Pigmentosa to Canada
The Phase III trial is evaluating the gene therapy, OCU400, in retinitis pigmentosa patients with RHO gene mutations and in a gene-agnostic cohort.
Pfizer's Hemophilia B Gene Therapy Approved in Canada
It marks the second gene therapy approval for treating hemophilia B in Canada in recent months.
NKGen Biotech Cleared to Start Clinical Trial of Alzheimer's Cell Therapy in Canada
The Santa Ana, California-based firm has already launched clinical trials of the autologous cell therapy in the US and Mexico.
Health Canada Approves CSL Behring's Hemgenix Gene Therapy
Hemgenix holds the distinction as the most expensive drug in the world after its approval in the US, where it's priced at $3.5 million.
Health Canada Approves Rhythm Pharmaceuticals' Weight Management Drug for Patients With MC4R Variants
Imcivree, already approved in the US and UK, will be available for adult and pediatric patients at least 6 years of age with obesity due to certain genetic mutations.